• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Selecting Optimal First-line Therapy for Patients Diagnosed with Heart Failure


Utilization of the four pillars in heart failure therapy are highlighted as aggressive first-line treatment strategies.

This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. The panel discusses treatment approaches for midrange ejection fraction heart failure with reduced ejection fraction (HFrEF). Albert notes there is no single approach; it depends on the individual patient. However, evidence supports, in some patients, starting all 4 pillar medications (angiotensin receptor-neprilysin inhibitors [ARNIs], angiotensin-converting enzyme [ACE] inhibitors or angiotensin receptor blockers [ARBs]; evidence-based beta blockers [metoprolol succinate, bisoprolol, carvedilol]; mineralocorticoid receptor antagonists [MRAs; spironolactone, eplerenone]; and sodium-glucose cotransporter-2 [SGLT2] inhibitors [dapagliflozin, empagliflozin]) within 2 weeks and optimizing doses within 1 month. Monitoring kidney function, potassium, and sodium guides safe intensification. The approach should be urgent, avoiding a “stable” mindset. Desai emphasizes the mortality benefits of quadruple therapy in HFrEF, yet real-world data shows only 1% of heart failure (HF) patients receive guideline-directed triple therapy. Like cancer, HF requires rapid multidrug therapy, not an incremental “start low, go slow” approach. The stakes are high to close evidence-practice gaps. Axsom draws an analogy to cancer and HF both being chronic life-threatening diseases demanding rapid treatment. Wright notes the multidirectional relationship between conditions like HF, kidney disease, and diabetes, requiring combined management.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.

Related Videos
Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"
Video 1 - "Conditions for Administering Bispecific Therapy"
Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology
Video 7 - "Future Opportunities in Genitourinary Cancers"
Video 6 - "LITESPARK-003 Trial Insights: Updates from ESMO 2023"
Video 5 - "Key Highlights from EV-302 Study at ESMO 2023"
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.
Dr Jennifer Brown
Related Content
© 2023 MJH Life Sciences
All rights reserved.